Funded equally by LUNGevity Foundation and the National Lung Cancer Partnership
Albert S. Baldwin, PhD
Lineberger Cancer Center, The University of North Carolina at Chapel Hill
Chapel Hill
Dr. Baldwin is identifying and testing new therapeutic targets for KRAS-positive lung cancer. KRAS activates the factor NF-κβ, which, when abnormally active, can contribute to the growth of lung tumors. This activation involves two kinases, and well-validated inhibitors of these pathways exist. This project is determining whether these inhibitors will block the initiation and/or progression of lung tumors.